A Phase 2 interventional study of andexanet alfa in Surgery, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 56 sites in 6 countries. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2023-03-22.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 303 studies in Thrombosis with a site in United States — 43 open to participants now, 49 under way, 5 of them phase 3. Thrombosis · United States.
Among the 303 studies in Thrombosis with a site in United States, this one is the 166th largest by enrollment of the 188 interventional ones that give a count, is one of 12 that started in 2021, is one of 38 in phase 2, and was the 222nd registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →43 of the 303 studies in Thrombosis with a site in United States are open now. Recruiting first, the newest first:
Columbia University · Sites in United States
Ages 18–80
Regeneron Pharmaceuticals · Sites in United States, Canada, Japan
Ages 18+
OHSU Knight Cancer Institute · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, United Kingdom
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 84 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
303 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 45 · Phase 3 38 · Phase 4 30
First in 1996; this study’s year is marked. 12 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 67 across the 188 interventional studies, 154 across the 112 observational. Of the 228 that completed or were terminated, 94 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
110 of 303 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
AstraZeneca has 3 studies filed under Thrombosis — fewer than ten, so there is no comparison to draw.
15 of the studies in Thrombosis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07560306Phase 3Brigham and Women's Hospital[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | 2027-03-30 |
| NCT05967741University of California, DavisThe Effects of Dietary Erythritol on Platelet Reactivity and Vascular Inflammation | 2026-12 |
| NCT04299828Boston Children's HospitalEvaluation of Pro-Inflammatory Leukocyte Activity in Patients Undergoing Cardiac Surgery | 2026-12 |
| NCT06434207Boston Children's HospitalExtracellular Vesicle Micro RNA Profiling in Congenital Heart Disease: Fetal-Maternal Regulation in Neonatal Thrombosis | 2026-12-01 |
| NCT04790240All Natural Medicine Clinic, LLCMedical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) | 2026-12-30 |
Add all 15 to your calendar (.ics) → With an account.
Among the 303 studies in Thrombosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.
This is a multicenter, prospective, open-label study to determine the efficacy and safety of andexanet in patients who require urgent surgery who have received 1 of the following FXa inhibitors: apixaban, rivaroxaban, edoxaban, or enoxaparin. The start of surgery must be within 15 hours following the last dose of FXa inhibitor. The primary efficacy outcome will be adjudicated by an independent Endpoint Adjudication Committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All of the following criteria must be met for the patient to be eligible:
Exclusion Criteria:
If a patient meets any of the following criteria, he or she is not eligible:
Acute life-threatening bleeding (ISTH criteria) at the time of Screening:
The patient has received any of the following drugs or blood products within 7 days of enrollment:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Andexanet is a recombinant version of human FXa
Also known as: Andexxa®, Ondexxya®
Number of Participants Achieving Effective Hemostasis
Effective hemostasis is defined as excellent or good as assessed by the Investigator; Ineffective hemostasis is defined as moderate or poor as assessed by the Investigator. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.
Time frame: Hemostasis will be assessed from the start of surgery to the end of the procedure
Percent Change From Baseline In Anti-fXa Activity To Treatment Nadir
Baseline is defined as the last non-missing value on or before first study drug administration. On treatment nadir is the minimum value of anti-fXa activity during the period of time from the end of the andexanet bolus to the end of the andexanet infusion. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.
Time frame: Baseline, Treatment nadir (not to exceed a total of 6.5 hours of andexanet dosing)
Participants who required urgent surgery and received factor Xa (fXa) inhibitors (apixaban, rivaroxaban, edoxaban, or enoxaparin) before surgery were enrolled in the study.
| Milestone | Andexanet Alfa |
|---|---|
| Started | 10 |
| Treated with any amount of andexanet | 10 |
| Efficacy set | 6 |
| Completed | 5 |
| Not completed | 5 |
| Withdrew: Death | 5 |
Effective hemostasis is defined as excellent or good as assessed by the Investigator; Ineffective hemostasis is defined as moderate or poor as assessed by the Investigator. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.
| Participants | Andexanet Alfa |
|---|---|
| Number of Participants Achieving Effective Hemostasis | 6 |
Baseline is defined as the last non-missing value on or before first study drug administration. On treatment nadir is the minimum value of anti-fXa activity during the period of time from the end of the andexanet bolus to the end of the andexanet infusion. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.
| Percent Change | Andexanet Alfa |
|---|---|
| Percent Change From Baseline In Anti-fXa Activity To Treatment Nadir | -96.13 (-97.4 to -89.2) |
Collected over Day 1 up to Day 37. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Andexanet Alfa | 5/10 (50%) | 7/10 (70%) | 2/10 (20%) |
| Event | Andexanet Alfa |
|---|---|
| Stress cardiomyopathyCardiac disorders | 1/10 |
| Periprosthetic fractureInjury, poisoning and procedural complications | 1/10 |
| Postprocedural hematomaInjury, poisoning and procedural complications | 1/10 |
| Ischaemic strokeNervous system disorders | 1/10 |
| Acute kidney injuryRenal and urinary disorders | 1/10 |
| Respiratory arrestRespiratory, thoracic and mediastinal disorders | 1/10 |
| ThrombosisVascular disorders | 1/10 |
| Event | Andexanet Alfa |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/10 |
| Vitamin B complex deficiencyMetabolism and nutrition disorders | 1/10 |
| Acute kidney injuryRenal and urinary disorders | 1/10 |
| Vitamin D deficiencyMetabolism and nutrition disorders | 1/10 |
Safety Set: Participants who were enrolled into the study and treated with any amount of andexanet alfa. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.
| Age, Continuous(Years) | Andexanet Alfa |
|---|---|
| Mean | 79.8 (68 to 84) |
| Sex: Female, Male(Participants) | Andexanet Alfa |
|---|---|
| Female | 7 |
| Male | 3 |
| Ethnicity (NIH/OMB)(Participants) | Andexanet Alfa |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 6 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Andexanet Alfa |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 6 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Ran from Jun 2021 to primary completion in Nov 2021, 4 months.
Results were first posted in Mar 2023, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PRT064445
Alexion Pharmaceuticals, Inc. →